Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen)

被引:57
作者
Boucher, E [1 ]
Corbinais, S
Brissot, P
Boudjema, K
Raoul, JL
机构
[1] Ctr Reg Lutte Contre Canc, F-35062 Rennes, France
[2] CHU Rennes, Serv Malad Foie, F-35033 Rennes, France
[3] CHU Rennes, Serv Chirurg Digest, F-35033 Rennes, France
[4] Ctr Eugene Marquis, F-35062 Rennes, France
关键词
hepatocellular carcinoma; systemic chemotherapy; ECF regimen; therapy;
D O I
10.1007/s00280-002-0503-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: We tested the efficacy of a systemic chemotherapy regimen combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF) in a cohort of patients with hepatocellular carcinoma (HCC) who could not be given surgical, intraarterial or percutaneous treatment. Patients and methods: Between January 1998 and June 2000, 21 patients with metastatic and/or locally advanced HCC complicating a fibrous liver or a well-compensated (Child A) cirrhosis were given systemic chemotherapy with the ECF regimen. Tumor responses as assessed on CT scan and in terms of survival were studied. Results: Patients completed a median of five chemotherapy courses. Overall tolerance was good but eight patients developed grade 3-4 toxicity, mainly hematological, and one patient experienced a grade 4 renal toxicity. Median survival was 10 months. Actuarial survivals (+/- SD) at 6 months, I year and 2 years were 90.2 +/- 9 %, 70.3 +/- 10 % and 24.6 +/- 19%, respectively. Of the 21 patients, 13 died, 12 from their tumor and I from treatment-related renal failure. There were only three objective responses (14.5%; CI95 1-28%) but one of these corresponded to a pathological complete response. The delay to tumor progression was 5.9 +/- 4.7 months. Conclusions: Systemic chemotherapy using the ECF regimen gave a poor response and low survival rates. It would appear reasonable to pursue the search for potentially efficacious chemotherapy protocols using other drug combinations.
引用
收藏
页码:305 / 308
页数:4
相关论文
共 28 条
  • [1] Aguayo A, 2001, Clin Liver Dis, V5, P175, DOI 10.1016/S1089-3261(05)70160-4
  • [2] Prevention in liver disease
    Arguedas, MR
    Fallon, MB
    [J]. AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2001, 321 (02) : 145 - 151
  • [3] Epirubicin and etoposide combination chemotherapy to treat hepatocellular carcinoma patients: A phase II study
    BobbioPallavicini, E
    Porta, C
    Moroni, M
    Bertulezzi, G
    Civelli, L
    Pugliese, P
    Nastasi, G
    [J]. EUROPEAN JOURNAL OF CANCER, 1997, 33 (11) : 1784 - 1788
  • [4] PHASE-II STUDY OF ORAL VP-16-213 IN HEPATOCELLULAR-CARCINOMA
    CAVALLI, F
    ROZENCWEIG, M
    RENARD, J
    GOLDHIRSCH, A
    HANSEN, HH
    [J]. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1981, 17 (10): : 1079 - 1082
  • [5] Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis
    Curley, SA
    Izzo, F
    Ellis, LM
    Vauthey, JN
    Vallone, P
    [J]. ANNALS OF SURGERY, 2000, 232 (03) : 381 - 389
  • [6] EPIRUBICIN, CISPLATIN AND INFUSIONAL 5-FLUOROURACIL (5-FU) (ECF) IN HEPATOBILIARY TUMORS
    ELLIS, PA
    NORMAN, A
    HILL, A
    OBRIEN, MER
    NICHOLSON, M
    HICKISH, T
    CUNNINGHAM, D
    [J]. EUROPEAN JOURNAL OF CANCER, 1995, 31A (10) : 1594 - 1598
  • [7] FALKSON G, 1987, CANCER, V60, P2141, DOI 10.1002/1097-0142(19871101)60:9<2141::AID-CNCR2820600903>3.0.CO
  • [8] 2-4
  • [9] Liver transplantation for hepatocellular carcinoma
    Hemming, AW
    Cattral, MS
    Reed, AI
    Van der Werf, WJ
    Greig, PD
    Howard, RJ
    [J]. ANNALS OF SURGERY, 2001, 233 (05) : 652 - 658
  • [10] PROGNOSTIC FACTORS IN PATIENTS WITH HEPATOCELLULAR-CARCINOMA RECEIVING SYSTEMIC CHEMOTHERAPY - IDENTIFICATION OF 2 GROUPS OF PATIENTS WITH PROSPECTS FOR PROLONGED SURVIVAL
    IHDE, DC
    MATTHEWS, MJ
    MAKUCH, RW
    MCINTIRE, KR
    EDDY, JL
    SEEFF, LB
    [J]. AMERICAN JOURNAL OF MEDICINE, 1985, 78 (03) : 399 - 406